Navigation Links
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Date:10/27/2008

a tendon, ligament or joint capsule insertion to the bone, and dactylitis, a swelling of digits in the hands or feet, are estimated to affect more than one-third of people with psoriatic arthritis.

The Biologics License Application (BLA) and Marketing Authorization Application (MAA) for golimumab were submitted earlier in the year and are currently under review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA), respectively. The filings are based on the extensive clinical development program for golimumab, including data from five pivotal Phase 3 trials in rheumatoid arthritis (RA), psoriatic arthritis and ankylosing spondylitis.

About the GO-REVEAL Trial

The GO-REVEAL trial involved 405 adults with psoriatic arthritis. Subjects with at least three swollen and tender joints and active psoriatic skin lesions of at least 2 centimeters in diameter were randomly assigned to receive subcutaneous injections of placebo or golimumab (50 or 100 mg) at week 0 and every 4 weeks thereafter through the end of the study. At week 16, patients with inadequate arthritis response were switched to golimumab 50 mg (patients originally receiving placebo) or golimumab 100 mg (patients originally receiving golimumab 50 mg). At week 24 all placebo patients crossed over to active treatment with golimumab 50 mg. The primary endpoint was ACR 20 response at week 14 for combined golimumab groups and individual golimumab dose groups versus placebo.

Through week 24, the placebo-controlled portion of the study, 2 percent of golimumab-treated patients experienced serious adverse events (SAE) compared with 6 percent of patients in the placebo group. Injection site reactions (ISR) occurred in 5 percent of patients receiving golimumab and 3 percent of patients receiving placebo. One case of prostate cancer and 2 cases of basal cell carcinoma were reported in golimumab-treated patients. Through week 52, 5 percent of golimumab-treated pat
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care
5. Finesse Solutions Launches Improved E-Store for Sensors and Transmitters
6. Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception
7. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
8. Improved culture system for hepatitis C virus infection
9. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
(Date:8/21/2014)... Cord Blood Corporation (NYSE: CO ) (the ... for the first quarter of fiscal year 2015 on ... US.  The Company will host a ... 29, 2014 to discuss its financial performance and give ... by a question and answer session.  Interested parties may ...
(Date:8/21/2014)... 21, 2014 Ontotext S4 , ... Ontotext . Now the same enterprise hardened ... structured and unstructured data is available to start-ups and ... enterprise technology. Organizations that do not have resources to ... can use S4 since there is no need for ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2
... 16, 2011 Genesis Biopharma, Inc. (OTC ... developing targeted cancer therapies, today announced it is expanding ... various cancers.  The Company will focus on establishing a ... new strategy will be discussed during a presentation today ...
... SAN DIEGO, March 15, 2011 PR Newswire, ... solutions, today announced the extension of their exclusive ... be the preferred provider of content distribution services ... science association. (Logo: http://photos.prnewswire.com/prnh/20000306/PRNLOGO) ...
... Biotechnology company ImmusanT, Inc. today announced it ... is advancing its strategy to develop an immunotherapeutic ... disease. The company completed the acquisition of a ... Ltd., based in Melbourne, Australia, and secured seed ...
Cached Biology Technology:Genesis Biopharma Announces Plans to Develop Active Immunotherapy Platform 2PR Newswire and BIOCOM Purchasing Group Announce Renewal of Exclusive Partnership 2PR Newswire and BIOCOM Purchasing Group Announce Renewal of Exclusive Partnership 3Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy 2Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy 3Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy 4
(Date:8/22/2014)... the 29th Annual International Papillomavirus Conference shows that ... combats three types of human papillomavirus, including the ... cancer. , When tested in several cultured human ... HPV-18 and HPV-11 cells, according to Louise T. ... the findings at the Seattle conference. The National ...
(Date:8/22/2014)... can probably remember the after-effects, including pain, swelling or ... back against the injury. When tissue in the body ... tissue regeneration. An inflammatory response acts as a protective ... to heal after injuries such as wounds and burns. ... situations in which foreign material is introduced, for example ...
(Date:8/22/2014)... tea polyphenols are strong antioxidants and can ... spinal cord neurons against oxidative stress? Jianbo ... Hospital of Liaoning Medical University, China discovered ... stress and inhibit neuronal apoptosis, indicating green ... spinal cord neurons under oxidative stress. The ...
Breaking Biology News(10 mins):Tissue regeneration using anti-inflammatory nanomolecules 2
... have won national awards for their research on the ... northern spotted owl. Martin Raphael and Eric Forsman, research ... Station, were named recipients of the Wings Across the ... the station,s Olympia, Wash., lab and Forsman at the ...
... barrier (BBB) remains a major obstacle to the successful ... disorders, reports Genetic Engineering and Biotechnology News ... approaches to preserve the ability of the BBB to ... and to permit the passage of effective medicines for ...
... plant pollen grains, sperm cells, which carry the genetic ... within larger "companion" cells that are called pollen vegetative ... nourishment, and push them towards their targets during fertilization. ... Spring Harbor Laboratory (CSHL) led by Professor Robert Martienssen, ...
Cached Biology News:Federal scientists recognized for contributions to knowledge of bird ecology and habitat 2GEN reports on strategies to overcome blood-brain barrier 2CSHL scientists discover how 'companion' cells to sperm protect them from genetic damage 2CSHL scientists discover how 'companion' cells to sperm protect them from genetic damage 3
... The kit measures mitochondria intactness ... mitochondrial membrane potential. Features and Benefits: ... method for staining isolated mitochondria and ... Contains all the reagents required for ...
... dispensers save space and organize ... and other garb. They are ... for small parts used in ... acrylic. Many other sizes and ...
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Mammals microRNA Microarray ...
Biology Products: